Independent of Calorie Intake,Short-term Alternate-day Fasting Alleviates NASH,With Modulation of Markers of Lipogenesis,Autophagy,Apoptosis,and Inflammation in Rats

Abstract

Non-alcoholic steatohepatitis (NASH) is a worldwide health problem. Alternate-day fasting (ADF), although thought to be aggressive, has proven safety and efficacy. We aimed to evaluate the effect of short-term ADF against already established high-fat-fructose (HFF)-induced NASH, independent of the amount of calorie intake, and to study the effect of ADF on lipogenesis, apoptosis, and hepatic inflammation. Male Sprague Dawley rats were divided into two groups: (1) negative control and (2) NASH group fed on HFF for 9 weeks, and then randomized into two subgroups of either HFF alone or with ADF protocol for 3 weeks. The ADF could improve HFF-related elevation in serum lactate dehydrogenase and could decrease the mRNA expression of lipogenesis genes; acetyl CoA carboxylase, peroxisome proliferator-activated receptor γ, and peroxisome proliferator-activated receptor α; apoptotic genes caspase-3, p53, and inflammatory cyclo-oxygenase 2; and immunohistochemical staining for their proteins in liver with upregulation of LC3 and downregulation of P62 immunoexpression. Moreover, ADF ameliorated HFF-induced steatosis, inflammation, ballooning, and fibrosis through hematoxylin and eosin, Oil Red O, and Sirius Red staining, confirmed by morphometric analysis, without significant weight loss. Significant correlation of morphometric parameters with levels of gene expression was found. These findings suggest ADF to be a safe effective therapeutic agent in the management of NASH

Keywords

apoptosis calorie restriction fasting hepatocyte inflammation lipogenesis liver NAFLD NASH

Introduction

Non-alcoholic fatty liver disease (NAFLD) is a major health problem, with increasing incidence due to the dominance of obesity among adults and children.¹ NAFLD is characterized by hepatic steatosis, which may be complicated by inflammation and non-alcoholic steatohepatitis (NASH) that may progress to fibrosis, liver cancer, or hepatic failure. Currently, there is no efficient therapy against NASH.²

Alternate-day fasting (ADF) was studied as a nutritional interference for preventing disease progression and showed more efficiency in increasing adherence to dietary control than the classic calorie restriction.³ Moreover, ADF was used as a therapeutic remedy for many diseases related to obesity, for example, hypertension and diabetes, through its effect on glucose levels, insulin sensitivity, atherogenic lipids, inflammation, and apoptosis and through induction of autophagy.⁴

Although recognized as an aggressive intervention, ADF has long been used in many studies in rats with variable durations—even for 12 months in mice with proven safety and efficacy.⁵ It is well known that the longer the duration of fasting, the stronger the induction of autophagy, so fasting for 24 hr induces autophagy more than shorter regimens.⁶

Many reports have discussed the change in lipogenesis regulators, for example, acetyl CoA carboxylase (ACACA), peroxisome proliferator-activated receptor α (PPAR-α), and peroxisome proliferator-activated receptor γ (PPAR-γ); apoptosis regulators, for example, caspase-3, p53, B-cell lymphoma 2 (Bcl-2); inflammation regulators, for example, cyclo-oxygenase 2 (COX-2); and autophagy markers, for example, microtubule-associated protein 1 light chain 3α (LC3) and sequestrosome (SQSTM)1/p62 when challenged with a high-fat-fructose (HFF) diet.^7,8 Others discussed the effect of different fasting regimens on those regulators with basal diet.⁹ However, to date, there are few reports that studied the effect of intense short-term ADF on these regulators in the management of already established NASH with matched fed controls to exclude the role of decreased calorie intake.

Aim of the Study

This study aimed to assess the therapeutic effect of short-term ADF on HFF-induced NASH and tried to define the mechanisms of rat liver protection against HFF-induced chemical damage with matched fed controls to exclude the role of decreased calorie intake. For evaluation of the hepatoprotective mechanisms of ADF, alanine aminotransferase (ALT) and lactate dehydrogenase (LDH) levels in serum were measured by colorimetric assay. Liver expression of lipogenesis genes ACACA, PPAR-α, and PPAR-γ; apoptosis-related genes caspase-3, p53, and Bcl-2; and inflammation-related genes COX-2 genes was assessed by quantitative real-time PCR and immunohistochemistry for their proteins in liver with evaluation of immunoexpression of LC3 and P62—autophagy markers. Histopathological changes were evaluated by hematoxylin and eosin (H&E) with NAFLD activity scoring (NAS). Moreover, Oil Red O and Sirius-red staining were performed for liver sections to detect steatosis and fibrosis, respectively, with morphometric analysis of the results. Moreover, a study of the correlation of gene expression changes with histopathological changes was done.

Materials and Methods

Calculation of the Size of Sample

G*Power program was used to measure the size of the sample, following the procedure illustrated by Faul et al.¹⁰ Built on previous studies,^11
–16 we hypothesize that the means of the three groups were 0.45, 0.85, and 1.05 for Bcl-2; 1, 2.2, and 4.2 for COX-2; 0.52, 0.75, and 1 for PPAR-α; 1.15, 1.45, and 2 for PPAR-γ; 1.2, 1.8 and 2.2 for p53; 1.05, 1.7, and 2.3 for ACACA; 0.75, 0.82, and 1.25 for caspase-3; and 334, 894, and 1711 for LDH. Suppose the standard deviation was 0.18 for Bcl-2, 0.3 for COX-2, 0.1 for PPAR-α, 0.25 for PPAR-γ, 0.3 for p53, 0.25 for ACACA, 0.15 for caspase-3, and 213 for LDH, the effect size (f) would be 1.3858 for Bcl-2, 4.3998 for COX-2, 1.9602 for PPAR-α, 1.4079 for PPAR-γ, 1.3699 for p53, 2.0418 for ACACA, 1.4737 for caspase-3, and 2.6545 for LDH. Based on these assumptions, samples sizes of 12, 6, 9, 12, 12, 9, 12, and 9 for Bcl-2, COX-2, PPAR-α, PPAR-γ, p53, ACACA, caspase-3, and LDH, respectively, reach 95% power to identify the effect sizes at 5% alpha level, taking into consideration the least effect size (1.3699). One-way ANOVA with the three groups suggests sample sizes of the rats to be 4 per each group. A number of 12 reaches a power of 95% using the F-test to achieve a significance level of 0.050. We started the study with four rats as a negative control, whereas the NASH group had 12 rats. However, four rats from the NASH group were excluded at the ninth week due to death or extreme illness.

Animals, Diet, and Experimental Design

The study design is true experimental in vivo posttest-only control-group design. Sixteen adult male Sprague Dawley (SD) rats, 8–10 weeks old and weighing 250–300 g, were used. All rats were maintained under precise pathogen-free conditions in Medical Experimental Research Center (MERC) and housed in cages (animals were kept under the appropriate conditions of controlled humidity, temperature, and light) with accessible water and food ad libitum with 1 week of acclimatization. The experiments described in this study met the terms of Institutional Research Board (IRB) for animal use, Faculty of Medicine, Mansoura University, Egypt (approval code: R.20.12.1119.R1). Male rats were used because of their higher susceptibility to develop liver steatosis.¹⁷ Rats were divided, in a randomized manner, into two groups: a negative control group with allowed free access to basal diet (10% fat) and water ad libitum (n=4) and the NASH group (n=12) fed on HFF: 40% fat, 40% carbohydrate,¹⁸ and 10% fructose in drinking water for 9 weeks to induce NASH, and then randomized into two groups of either HFF only or HFF and ADF protocol (24-hr feeding and then 24-hr fasting) for the next 3 weeks. To exclude the role of decreased amount of calorie intake in the ADF subgroup, the HFF-alone subgroup was administered matched food intake similar to that measured in ADF rats. In the ADF group, food was removed on fasting days, whereas water intake was provided ad libitum. Weights were measured and recorded for the past 3 weeks. Regarding the safety of the ADF protocol on animals, it has long been used in many studies—even for 12 months in mice⁵—with proven safety and efficacy, so as a trial to limit the use of rats and limit the costs, we did not have to add a fasting control group, confirmed to be safe from these reports.

Blood Sampling

Samples of blood were taken under anesthesia from the retro-orbital sinus of rats at the end of the experiment in tubes with no EDTA. Blood samples were allowed to clot at room temperature, with consequent centrifugation and serum separation and storage at −20C until being examined.

Sacrification

Sacrification of rats was done through cervical dislocation, followed by excision and washing of livers by saline.

ALT and LDH Colorimetric Assays

To evaluate the condition of hepatocytes, serum ALT level and LDH activity were assessed using the ALT assay endpoint kit (MG; cat. no. MG264001) and LDH colorimetric kinetic assay (MG; cat. no. MG283001) and also using the Erba CHEM-7 device. The measurement of ALT was based on monitoring the concentration of pyruvate hydrazone formed through the reaction with 2,4-dinitrophenylhydrazine. The measurement of LDH was based on conversion of pyruvate to l-lactate by monitoring the oxidation of NADH. LDH activity was monitored over 3 min at an absorbance of 340 nm, and then the mean absorbance change per minute was calculated (∆A/min); the concentration of LDH was calculated according to the manufacturer’s specifications.¹⁹

mRNA Measurement by Real-time Reverse Transcription PCR

Liver samples were kept in RNAlater (500 µl was used for each 50 mg tissue sample) (Qiagen, Hilden, Germany), incubated overnight at 2–8C, and then removed from the reagent and transferred to −80C for storage until homogenization through the method described in our previous work.²⁰ The RNA yield was checked by Thermo Scientific NanoDrop 2000 (USA) for concentration using the absorbance of 260 nm and for purity using 260/280 and 260/230 ratios. Reverse transcription of 1 µg of RNA was performed using SensiFAST cDNA Synthesis Kit (Bioline, London, UK), with the following program (10 min at 25C for primer annealing, 15 min at 42C for reverse transcription, and 5 min at 85C for inactivation) on Applied Biosystems 2720 Thermal Cycler.

cDNA templates were amplified using a real-time PCR instrument (Applied Biosystems 7500). The amplification reaction contained a total reaction volume of 20μl (10μl of HERA SYBR green PCR Master Mix [Willowfort, UK], 2μl of cDNA template, 2μl [10 pmol/ μl] gene primer and 6μl of nuclease-free water), and in accordance with the following programme: 95C for 2 min, 40 cycles of 95C for 10 s, and 60C for 30 s. The primer sequences used are mentioned in Table 1. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) has been applied as a housekeeping gene. The primer sets were designated using Primer 3 software (v.4.1.0),²¹ and primer specificity was determined using the Primer- BLAST program.²² The specificity of the PCR products was also evaluated by melting curve analysis. Primer sets were synthesized by Vivantis (Vivantis Technologies, Shah Alam, Malaysia).

Table 1.

The Gene Sequence of Rat Primers.

Gene	Sequence	Product Length	RefSeq
Acetyl-CoA Carboxylase Alpha (ACACA)	Forward primer: ATATGTTCGAAGAGCTTATATCGCCTAT Reverse primer: TGGGCAGCATGAACTGAAATT	101 bp	NM_022193.1
Peroxisome proliferator-activated receptor γ (PPAR-γ)	Forward primer: GACCACTCCCATTCCTTTGA Reverse primer: AACCATTGGGTCAGCTCTTG	108 bp	NM_001145366.1
Peroxisome proliferator-activated receptor α (PPAR-α)	Forward primer: TCCTCTGGTTGTCCCCTTGA Reverse primer: CAGTCTTGGCTCGCCTCTAA	141 bp	NM_013196.1
Caspase 3	Forward primer: GGCCGACTTCCTGTATGCT Reverse primer: CGTACAGTTTCAGCATGGC	110 bp	NM_012922.2
Tumor protein p53 (Tp53)	Forward primer: CCCCTGAAGACTGGATAACTGTC Reverse primer: ATTAGGTGACCCTGTCGCTG	146 bp	XM_006246594.3
B-cell lymphoma 2 (Bcl-2)	Forward primer: GTACCTGAACCGGCATCTG Reverse primer: ATCAAACAGAGGTCGCATGC	97 bp	NM_016993.1
Cyclo-oxygenase 2 (COX-2)	Forward primer: GGAGCAACCGATGTGGAATTG Reverse primer: GCCGGTATCTGCCTTCATGT	104 bp	NM_017232.3
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)	Forward primer: TGCCACTCAGAAGACTGTG Reverse primer: GGATGCAGGGATGATGTTC	85 bp	NM_017008.4

Relative gene expression levels were represented as ΔCt = Ct target gene – Ct housekeeping gene; fold change of gene expression was calculated using the 2^−ΔΔCT method.²³ PCR products were run on 3% agarose gels with subsequent visualization and photographing (Figs. 3 –6).

Histopathology

A part of each liver was cut and frozen to be used for Oil Red O stain as described by Layman et al.²⁴ Another part was fixed in 10% formaldehyde and then embedded in paraffin²⁵ for histopathological examination. Next, the paraffin sections were cut into 7- to 10-µm-thick sections. The sections were stained with H&E and mounted on slides for evaluation of histopathological changes and by Sirius Red to detect the extent of fibrosis; Oil Red O staining was done in fresh frozen sections for detection of lipid droplets. The results were recorded as photomicrographs using an Olympus Microscope with SC100 Color.

NAFLD Activity Scoring

A semi-quantitative NAS was used to assess the severity of NAFLD in 24 simple random non-overlapping fields per group, scattered in the preparations as a representative sample (three fields per each section of two sections per rat for each rat of the four rats per group). Scoring assesses three major histological features: steatosis, hepatocellular ballooning, and inflammation. The total score is defined as the unweighted sum of the scores for steatosis (0–3), lobular inflammation (0–3), and ballooning (0–2), thus ranging from 0 to 8.²⁶

Immunohistochemical Staining

Immunohistochemistry was performed on 3-μm-thick sections according to the immunoperoxidase technique described in our previous work.²⁷ Briefly, the tissue sections were submitted for deparaffinization, and to block the endogenous peroxidase, hydrogen peroxide with 0.3% methanol was added to the liver sections for 10 min at room temperature. This was followed by heating the liver sections at 95C in 10 mM citrate buffer for 10 min to stimulate antigen retrieval, and then the sections were left for 60 min to cool. After that, the sections were incubated with the primary antibodies for ACACA, PPAR-γ, PPAR-α, caspase-3, p53, Bcl-2, COX-2, LC3, and P62 overnight at 4C. Table 2 includes the details of the primary antibodies and the dilutions used. This was followed by maintaining the slides with secondary anti-mouse antibody (sc-516102; Santa Cruz, Dallas, USA) for half an hour. Finally, DAB was added for 4 min, and then the sections were counterstained by hematoxylin. For the reagent (no primary antibody) control, PBS was added as a substitute for the primary antibody. Finally, the sections were washed, dehydrated, and examined by light microscope. Dark brown areas in the cytoplasm or nucleus demonstrate positive staining, and the background is blue. Antigen localization was cytoplasmic for the expression of ACACA, caspase-3, Bcl-2, COX-2, LC3, and P62; nuclear for the expression of p53; and finally nuclear and cytoplasmic for the expression of PPAR-γ and PPAR-α.

Table 2.

The Primary Antibodies Applied for Immunohistochemistry.

	Name	Cat. No.		Clonality	Clone Number	Dilution
Primary antibodies	ACACA	Santa Cruz	sc-137104	Mouse monoclonal	D-5	1/100
	PPAR-γ		sc-7273		E-8	1/40
	PPAR-α		sc-398394		H-2	1/200
	Caspase-3		sc-65497		4.1.18	1/50
	p53		sc-126		DO-1	1/100
	Bcl2		sc-7382		C-2	1/50
	COX2		sc-19999		29	1/200
	LC3		sc-271625		G-2	1/200
	SQSTM1/P62		sc-48402		A-6	1/200

Abbreviations: ACACA, acetyl CoA carboxylase; PPAR-γ, peroxisome proliferator-activated receptor γ; PPAR-α, peroxisome proliferator-activated receptor α; p53, tumor protein p53; Bcl-2, B-cell lymphoma 2; COX-2, cyclo-oxygenase 2.

Morphometric Analysis

Morphometric analysis of area fraction of fat stained by Oil Red O and collagen stained by Sirius Red was performed using ImageJ software Version 1.52a²⁸ and Fiji ImageJ software.²⁹ In brief, to isolate red-stained collagen or fat, we changed the image type to RGB Stack that yields the gray-scale images of the channels (Image → Type → RGB Stack). In the Green channel, we set the threshold at 0–87 (Image → Adjust → Threshold). We recorded the area, area fraction, limit to threshold, and display label (Analyze → Measure). Moreover, the immunohistochemical results were assessed by counting the number of immunopositive cells (brown nuclei in PPARs and p53 and brown cytoplasm in other proteins) in the whole high-power field (×400) of a total of 24 simple random non-overlapping fields per group, scattered in the preparations as a representative sample (three fields per each section of two sections per rat for each rat of the four rats per group) and then measuring the percentage of number of positive cells to the total number of cells in the field.

Statistical Analysis

Data were entered and analyzed using SPSS (IBM Corp. Released 2017. IBM SPSS Statistics for Windows, Version 25.0. Armonk, NY: IBM Corp.). Quantitative data were initially tested for normality using Shapiro–Wilk’s test, with data being normally distributed if p>0.050. The presence of significant outliers was tested for by examining boxplots. Normally distributed quantitative data were expressed as mean ± standard error (SE), whereas quantitative non-normally distributed and ordinal data were expressed as median (range). To compare the quantitative data between the studied groups, one-way ANOVA was used. Post hoc assessment was applied for proper comparison between the data. Tukey adjustment was used to check the assumption of equal variances, whereas Games-Howell adjustment was used when assumption of equal variances was violated. Kruskal–Wallis H-test with pairwise comparisons was used to compare ordinal data between the three study groups. Pearson’s correlation was used to assess the strength and to evaluate the direction of a linear relationship between the continuous variables when having normally distributed values. Spearman’s correlation was applied to assess the strength and to evaluate the direction of a linear relationship between continuous and ordinal variables. The results were thought to be significant, for any test used, when p value was ≤0.050.

Results

Assessment of Weight Change

During the last 3 weeks of the experiment (after admitting for the ADF protocol), the NASH group exhibited the faster body weight gain and significant greater final body weights when compared with the negative control group (p=0.018). However, the ADF regimen caused insignificant change when compared with the NASH group (p=1.000). Moreover, the ADF group did not show a significant difference from the negative group (p=0.150) (Table 3).

Table 3.

Percentage of Weight Change in the Studied Groups.

Parameter	Group			H Value	P Value
Parameter	Negative Control (n=4)	NASH (n=4)	NASH With ADF (n=4)	H Value	P Value
% of weight change	5.90(4.17–8.33)A	15.45 (10.47–42.11)B	13.77(9.41–19.72)AB	1.333	0.018

Data are expressed as median (range). P value by Kruskal–Wallis H-test (different letters = significant difference); significant p value is considered when ≤0.05. Abbreviations: NASH, non-alcoholic steatohepatitis; ADF, alternate-day fasting.

Effect of ADF on Serum ALT and LDH

The effect of ADF on HFF-related NASH in rats was evaluated by changes in serum ALT and LDH in Table 4. Regarding serum ALT, it showed a highly significant increase in the NASH group compared with the negative control group (p<0.0005) and showed another significant increase in the ADF group when compared with the NASH group (p=0.001). In addition, compared with the negative control group, serum ALT level in the ADF group showed a high significant increase (p<0.0005). Moreover, Games-Howell pairwise comparisons demonstrated that LDH showed a high significant increase in the NASH group compared with the negative control group (p<0.0005). This finding was inverted in the ADF group, displaying a significant decrease in serum LDH when compared with the NASH non-treated group (p<0.0005), but there was a non-significant difference between the ADF group and the negative control group (p=0.997).

Table 4.

Serum Levels of ALT and ADH in the Studied Groups.

Parameter	Group			F Value	P Value	Partial eta Squared
Parameter	Negative Control (n=4)	NASH (n=4)	NASH With ADF (n=4)	F Value	P Value	Partial eta Squared
ALT (IU/l)	19.13 ± 1.64A	40.65 ± 0.20B	50.36 ± 2.18C	102.387	<0.0005	0.782
LDH (U/l)	869.75 ± 52.86A	1824.25 ± 124.99B	878.25 ± 101.01A	31.552	<0.0005	0.525

Establishment of NASH Model and Studying the Effect of ADF on Gross and Histopathological Changes

The livers of rats fed HFF diet established the pathological characters of NASH according to NAS, with variable grades of steatosis, hepatocellular ballooning, and inflammation. Livers of the NASH group are swollen with yellowish tinge, which is corrected by ADF. The negative control group shows the normal liver architecture, whereas the NASH group shows widespread macrovesicular and microvesicular steatosis with ballooning, as well as inflammatory cells that were more centrilobular. However, ADF reduced macrovesicular steatosis with less ballooning and microvesicular steatosis and inflammation (Fig. 1). Oil Red O staining showed extensive reaction for fat in the high-fat diet (HFD) group with moderate reaction in the ADF group. Sirius Red staining showed a strong staining for collagen fibers in the periportal and perivenous areas with multiple septa in the HFD group with moderate staining in the ADF group (Fig. 2).

Figure 1.

Representative photographs of liver gross appearance (A, B, and C). (A) Negative control rats, (B) HFF diet–induced NASH group, and (C) ADF group. NASH livers are swollen with yellowish tinge, which is corrected by ADF. Hematoxylin and eosin (H&E) staining (×400) in the periportal region (D, F, and H) and the centrilobular region (E, G, and I). Scale bar = 50 µm. H&E of the negative control group shows normal liver architecture (D and E) with cords of hepatocytes radiating from the central vein (black arrows), whereas the NASH group (F and G) demonstrates diffuse macrovesicular steatosis (asterisks), ballooned hepatocytes (yellow arrow head), microvesicular steatosis (black arrows), and inflammatory cells (yellow arrows) that were more centrilobular (G). However, ADF (H and I) reduced macrovesicular steatosis (asterisks), few ballooned hepatocytes (yellow arrow head), steatosis (black arrows), and inflammation. Abbreviations: HFF, high-fat-fructose; NASH, non-alcoholic steatohepatitis; ADF, alternate-day fasting; H, hepatic artery; P, portal vein; B, bile duct; C, central vein

Figure 2.

Oil Red O–stained section (×400) (A, B, and C) and Sirius Red–stained section (×100) magnification (E, F, and G). Scale bar = 50 µm. Negative control rats (A and E). HFF diet–induced NASH group (B and F) and ADF group (C and G). Note the mild reaction for fat in the negative control group (A) and strong reaction for fat in the NASH group (B) with moderate reaction in the ADF group (C). Note the mild reaction for collagen in periportal (P) and perivenous (C) areas (E), the strong reaction for collagen in the NASH group (F) around portal tract and central vein with multiple septa (black arrows), and the moderate staining in the ADF group (G). Area percentage of Oil Red O–stained sections (D) and area percentage of Sirius Red–stained sections (H). Data are expressed as mean ± SD (n=4/group). P value by one-way ANOVA, followed by post hoc test “Tukey adjustment” is presented (different letters = significant difference). P value is considered significant when it is ≤0.05. For Oil Red, p<0.0005, F = 151.824, and partial eta squared = 0.971, whereas for Sirius Red, p<0.0005, F = 328.789 and partial eta squared = 0.986. Abbreviations: HFF, high-fat-fructose; NASH, non-alcoholic steatohepatitis; ADF, alternate-day fasting.

Results of NAS and Morphometric Analysis for Sirius Red–stained and Oil Red O–stained Area

There was a statistically significant difference in NAS and morphometric analysis for Sirius Red–stained and Oil Red O–stained area between the three groups (p<0.0005). Games-Howell post hoc comparison for the NAFLD scoring results revealed significantly increased values in the NASH group (p=0.005), with significant decrease in the NASH group treated with ADF compared with the NASH group (p=0.043); moreover, comparing the ADF group with the negative control group showed a high significant difference (p<0.0005). The NASH group shows more steatosis (p<0.0005), ballooning (p<0.0005), and inflammatory cells (p<0.0005) compared with the negative control. However, ADF reduced the steatosis (p=0.002) with less ballooning (p=0.120) and inflammation (p=0.036) when compared with the NASH group (Table 5). Tukey post hoc comparison for the Oil Red and Sirius Red analysis showed a high significant increase in the NASH group when compared with the negative control group (p<0.0005 for both); also, there was a high significant decrease in the ADF group compared with the NASH group (p<0.0005 for both) and a high significant difference between the ADF group and the negative control group (p<0.0005 for both) (Fig. 2).

Table 5.

Results of NAS.

Parameter	Groups			H	P Value
Parameter	Negative Control (n=4)	NASH (n=4)	NASH + ADF (n=4)	H	P Value
Ballooning	0.00 (0.00–0.00)A	2.00 (1.00–2.00)B	1.00 (1.00–1.00)B	47.791	<0.0005
Steatosis	0.00 (0.00–1.00)A	3.00 (2.00–3.00)B	1.00 (1.00–2.00)C	49.692	<0.0005
Inflammation	0.00 (0.00–0.00)A	1.00 (1.00–3.00)B	1.00 (0.00–2.00)C	37.644	<0.0005
NAS	0.00 (0.00–1.00)A	6.00 (3.00–7.00)B	3.00 (2.00–4.00)C	52.354	<0.0005

Data are expressed as median (interquartile range). P value by Kruskal–Wallis H-test (different letters = significant difference); significant p value is considered when ≤0.05. Abbreviations: NASH, non-alcoholic steatohepatitis; ADF, alternate-day fasting; NAS, NAFLD activity scoring.

Immunohistochemical Results

Immunohistochemical detection of lipogenesis proteins ACACA, PPAR-γ, and PPAR-α in the liver sections of the negative control group showed a weak immunoreactivity. Noticeable, hepatocytes of the NASH group showed an intense cytoplasmic expression of ACACA and nuclear and cytoplasmic expression of PPAR-γ and PPAR-α. In contrast, hepatocellular immunoreactivity was ameliorated in the ADF group (Figs. 3 and 4). Immunohistochemical detection of apoptosis-related proteins caspase-3, p53, Bcl-2, and inflammatory COX-2 in liver sections of the negative control group showed a weak immunoreactivity. Noticeable, livers of the NASH group showed an intense cytoplasmic expression for caspase-3, Bcl-2, and COX-2. Caspase-3- and COX-2-positive staining was seen in the ballooned hepatocytes and inflammatory cells, too, with positive p53 nuclear immunoreaction in the hepatocytes. In contrast, this immunoreactivity was ameliorated in the ADF group (Figs. 4 –6). Immunohistochemical detection of autophagy markers LC3 and P62 in liver sections of the negative control group showed a weak immunoreactivity. Noticeable, hepatocytes of the NASH group showed a weak cytoplasmic expression for LC3 with an intense cytoplasmic expression for P62. In contrast, the ADF group showed a strong expression for LC3 with a weak expression for P62 (Fig. 7).

Figure 3.

Immunohistochemical staining for lipogenesis markers ACACA (A, B, and C) and PPAR-γ (E, F and G) in liver tissues in negative, NASH, and ADF groups. Magnification, ×400. Scale bar = 50 µm. Arrows: immunopositive cells. Gel photographs of the studied genes ACACA (D) and PPAR-γ (H). ACACA qPCR product (101 bp), PPAR-γ (108 bp), and GAPDH (85 bp). N.B.: Image of GAPDH gel electrophoresis was repeated with images of other genes as it was used as a control gene. Abbreviations: L, ladder NASH, non-alcoholic steatohepatitis; ADF, alternate-day fasting; ACACA, acetyl CoA carboxylase; PPAR-γ, peroxisome proliferator-activated receptor γ; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

Figure 4.

Immunohistochemical staining for lipogenesis marker PPAR-α (A, B, and C) and apoptotic marker caspase-3 (E, F, and G) in liver tissues in negative, NASH, and ADF groups. Magnification, ×400. Scale bar = 50 µm. Arrows: immunopositive cells. Gel photographs of the studied genes PPAR-α (D) and caspase-3 (H). PPAR-α qPCR product (141 bp), caspase-3 (110 bp), and GAPDH (85 bp). Image of GAPDH gel electrophoresis was repeated with images of other genes as it was used as a control gene. Abbreviations: L, ladder; NASH, non-alcoholic steatohepatitis; ADF, alternate-day fasting; PPAR-α, peroxisome proliferator-activated receptor-α; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

Figure 5.

Immunohistochemical staining for apoptosis marker p53 (A, B, and C) and antiapoptotic marker Bcl-2 (E, F, and G) in liver tissues in negative, NASH, and ADF groups. Magnification, ×400. Scale bar = 50 µm. Arrows: immunopositive cells. Gel photographs of the studied genes p53 (D) and Bcl-2 (H). P53 qPCR product (146 bp), Bcl-2 (97 bp), and GAPDH (85 bp). Image of GAPDH gel electrophoresis was repeated with images of other genes as it was used as a control gene. Abbreviations: L, ladder; NASH, non-alcoholic steatohepatitis; ADF, alternate-day fasting; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; p53, tumor protein p53; Bcl-2, B-cell lymphoma 2.

Figure 6.

Immunohistochemical staining for Cox-2 in liver tissues in negative control, NASH, and ADF groups (A, B, and C). Magnification, ×400. Scale bar = 50 µm. Arrows: immunopositive cells. Gel photographs of COX-2 vs GADPH (D). COX2 (104 bp) and GAPDH (85 bp). Abbreviations: L, ladder; NASH, non-alcoholic steatohepatitis; ADF, alternate-day fasting; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; COX-2, cyclo-oxygenase 2.

Figure 7.

Immunohistochemical staining for autophagy markers LC3 (A, B, and C) and P62 (D, E, and F) in liver tissues in negative, NASH, and ADF groups. Magnification, ×400. Scale bar = 50 µm. Arrows: immunopositive cells. Abbreviations: NASH, non-alcoholic steatohepatitis; ADF, alternate-day fasting.

Morphometric Analysis of Immunohistochemical Results

Immunohistochemical results in the study groups were assessed by morphometric analysis for the mean and standard error of percentage of the number of immunopositive cells to the number of whole cells in the field (Table 6). There was a statistically significant difference in all morphometric parameters between the three groups (p<0.0005), except for Bcl-2 and PPAR-α (p=0.158 and 0.148, respectively) which showed insignificant increase in the NASH group. Games-Howell post hoc analysis for ACACA, PPAR-γ, caspase-3, p53, COX2, LC3, and P62 proteins revealed that the percentage of immunopositive cells was the highest in the NASH group (p<0.0005 for all parameters), with a significant decrease in the ADF group (p<0.0005 for all parameters).

Table 6.

Percentage of Protein-positive Cells in Rat Liver Tissues From the Three Studied Groups.

Parameter	Group			F Value	P Value	Partial eta Squared
Parameter	Negative Control (n=4)	NASH (n=4)	NASH With ADF (n=4)	F Value	P Value	Partial eta Squared
ACACA	2.00 ± 0.11A	23.27 ± 0.63B	14.88 ± 0.47C	550.540	<0.0005	0.951
PPAR-γ	9.42 ± 0.29A	37.71 ± 1.33B	22.62 ± 0.68C	259.536	<0.0005	0.901
PPAR-α	15.02 ± 2.07	19.86 ± 1.49	17.63 ± 1.65	1.906	0.158	0.063
Caspase-3	0.46 ± 0.02A	4.68 ± 0.18B	1.82 ± 0.09C	350.087	<0.0005	0.925
P53	1.18 ± 0.07A	15.84 ± 0.53B	9.13 ± 0.32C	421.319	<0.0005	0.937
Bcl-2	8.83 ± 1.28A	12.32 ± 1.22A	10.70 ± 1.24A	1.974	0.148	0.065
COX2	4.90 ± 0.22A	35.25 ± 1.81B	17.57 ± 0.69C	183.403	<0.0005	0.866
LC3	10.03 ± 0.33A	7.65 ± 0.83B	19.06 ± 0.62C	171.627	<0.0005	0.858
P62	5.90 ± 0.19A	22.63 ± 0.80B	13.57 ± 0.41C	1401.915	<0.0005	0.898

Data are expressed as mean ± SE. P value by one-way ANOVA, followed by post hoc test “Games-Howell adjustment” (different letters = significant difference); p value is considered significant when it is ≤0.05 and demonstrated in boldface. Abbreviations: NASH, non-alcoholic steatohepatitis; ADF, alternate-day fasting, ACACA, acetyl CoA carboxylase; PPAR-γ, peroxisome proliferator-activated receptor γ; PPAR-α, peroxisome proliferator-activated receptor α; p53, tumor protein p53; Bcl-2, B-cell lymphoma 2; COX-2, cyclo-oxygenase 2.

Effect of ADF on mRNA Gene Expression

There was a significant difference in the studied genes between the three groups (p values were 0.005, 0.021, <0.0005, 0.018, and 0.005 for ACACA, PPAR-γ, caspase-3, p53, and COX-2, respectively) except for Bcl-2 and PPAR-α (p=0.187 and 0.407, respectively) showing insignificant higher expression in the NASH group. Post hoc Tukey adjustment for the other genes showed a significant increase in all gene expressions in the NASH group when compared with the NASH + ADF and negative control groups (Figs. 3 –6). Regarding ACACA mRNA expression, it showed a significant increase in the NASH group when compared with the negative control group (p=0.006) and a significant decrease in the ADF group when compared with the NASH group (p=0.015), but a non-significant difference between the ADF group and the negative control group (p=0.826). Regarding PPAR-γ mRNA expression, it showed a significant increase in the NASH group when compared with the negative control group (p=0.033) and a significant decrease in the ADF group when compared with the NASH group (p=0.036), but a non-significant difference between the ADF group and the negative control group (p=0.998). Regarding caspase-3 mRNA expression, it showed a significant increase in the NASH group when compared with the negative control group (p<0.0005) and a significant decrease in the ADF group when compared with the NASH group (p=0.001); also, there was a barely missed statistical significant difference between the ADF group and the negative control group (p=0.054). For the p53 mRNA expression, there was a significant increase in the NASH group when compared with the negative control group (p=0.037) and a significant decrease in the ADF group when compared with the NASH group (p=0.024), but a non-significant difference between the ADF group and the negative control group (p=0.956). For the COX2 mRNA expression, there was a significant increase in the NASH group when compared with the negative control group (p=0.009) and a significant decrease in the ADF group when compared with the NASH group (p=0.010), but a non-significant difference between the ADF group and the negative control group (p=0.992) (Table 7).

Table 7.

Relative Quantification of the Studied Genes in Rat Liver Tissues From the Three Studied Groups.

Parameter	Group			F Value	P Value	Partial eta Squared
Parameter	Negative Control (n=4)	NASH (n=4)	NASH With ADF (n=4)	F Value	P Value	Partial eta Squared
ACACA	0.93 ± 0.56A	5.64 ± 1.04B	1.61 ± 0.71A	10.187	0.005	0.694
PPAR-γ	0.84 ± 0.39A	2.94 ± 0.60B	0.88 ± 0.44A	6.111	0.021	0.576
PPAR-α	0.61 ± 0.18A	1.70 ± 0.58A	0.92 ± 0.30A	2.035	0.187	0.311
Caspase-3	1.06 ± 0.21A	4.04 ± 0.28B	2.01 ± 0.25C	38.139	<0.0005	0.894
P53	0.95 ± 0.37A	2.29 ± 0.15B	0.82 ± 0.38A	6.55	0.018	0.593
Bcl-2	0.92 ± 0.44A	1.77 ± 0.17A	1.42 ± 0.57A	0.994	0.407	0.181
COX2	0.48 ± 0.20A	4.44 ± 1.16B	0.60 ± 0.35A	10.011	0.005	0.690

Data are expressed as mean ± SE. P value by one-way ANOVA, followed by post hoc test “Tukey adjustment” (different letters = statistically significant difference); p value is considered significant if it is ≤0.05 and demonstrated in boldface. Abbreviations: NASH, non-alcoholic steatohepatitis; ADF, alternate-day fasting, ACACA, acetyl CoA carboxylase; PPAR-γ, peroxisome proliferator-activated receptor γ; PPAR-α, peroxisome proliferator-activated receptor α; p53, tumor protein p53; Bcl-2, B-cell lymphoma 2; COX-2, cyclo-oxygenase 2.

Correlation of Morphometric Findings With Levels of Gene Expression

Study of the correlation of morphometric findings with levels of genes expression showed that all the three morphometric parameters that had a statistically significant positive correlation with ACACA, PPAR-α, caspase-3, p53, and COX-2 gene expression showed a significant negative correlation. Correlation was most strong with caspase-3. There was no statistically significant correlation between area fraction of Oil Red and PPAR-γ and Bcl-2. In addition, there was no statistically significant correlation between area fraction of Sirius Red and Bcl-2 (Table 8).

Table 8.

Correlation of the Morphometric Results With Gene Expression Profiles.

Gene	NAFLD Activity Scoring		Area Fraction of Oil Red		Area Fraction of Sirius Red
Gene	rs*	P value	r**	P value	r**	P value
ACACA	0.719	<0.0005	0.655	0.021	0.761	0.004
PPAR-γ	0.518	<0.0005	0.573	0.051	0.654	0.021
PPAR-α	0.368	0.004	0.597	0.040	0.576	0.050
Caspase-3	0.850	<0.0005	0.888	<0.0005	0.946	<0.0005
P53	0.593	<0.0005	0.582	0.047	0.689	0.013
Bcl-2	0.386	0.002	0.451	0.141	0.451	0.141
COX-2	0.667	<0.0005	0.616	0.033	0.712	0.009

Abbreviations: *rs, Spearman’s correlation coefficient; **r, Pearson’s correlation coefficient; P value is considered significant if it is ≤0.05 and demonstrated in boldface. ACACA, acetyl-CoA carboxylase alpha; PPAR-γ, peroxisome proliferator-activated receptor γ; PPAR-α, peroxisome proliferator-activated receptor α; p53, tumor protein p53; Bcl-2, B-cell lymphoma 2; COX-2, cyclo-oxygenase 2.

Discussion

Lipid accumulation in the liver represents an oxidative stressful event that leads to inflammation and NASH.³⁰ In this study, we used SD rats to assess whether ADF may be useful in alleviating the pathological effects of NASH. Steatosis, inflammation, ballooning of hepatocytes, and fibrosis were the most striking pathological changes observed by histopathological examination of the NASH group in accordance with the previous results of Fraulob et al.³¹ These changes were ameliorated by ADF. Similar positive effects of ADF were reviewed by Harvie and Howell.³² Surprisingly, the positive effect of ADF on NASH was independent of weight loss. Moreover, previous studies confirmed the significant ultrastructural changes in liver after fasting.³³ However, we have applied here an intense protocol of ADF (24 hr) as it is argued that 24-hr fasting of rat is not comparable with similar duration in human because the rat has a higher metabolic rate, for example, rat fasting for 5–6 hr offers a better comparison with human overnight fasting (16–18 hr),³⁴ meaning that 24-hr fasting in rat may mimic 72-hr fasting in human. So, applying a clinically comparable fasting protocol in human with 3 days of fasting may need to be tested well at first in experimental animals.

Serum ALT and LDH5, the markers of liver cell injury, were significantly elevated in the NASH group. This may be explained by the fact that HFF diet exerted a damaging effect on liver cells, releasing ALT and LDH5 to the blood. These findings were in agreement with the results of a previous study by Wu et al.³⁵ In contrast, ADF opposed this effect in LDH but not in ALT.

In this study, the NASH group showed a significant upregulation of PPAR-γ, whereas the ADF group showed a significant downregulation. These findings can be explained by the fact that PPAR-γ, expressed mainly in adipose tissue, can modulate lipid metabolism and inflammation.³⁶ This is also in agreement with Matsusue et al.,³⁷ who found that PPAR-γ promotes hepatic steatosis. In this study, ADF reversed this effect, indicating that ADF showed antilipogenic effect on NASH.

Moreover, NASH induced a significant upregulation in the ACACA gene expression, and this effect was also significantly ameliorated by ADF intervention. These findings can be explained by the fact that PPAR-γ induces the de novo lipogenesis enzymes fatty acid synthase and ACACA 1, in hepatocytes, facilitating an increase in hepatic triglycerides^37,38 and that the expression of enzymes involved in de novo lipogenesis like ACACA is controlled during fasting and refeeding, dietary carbohydrate, and dietary fat.^39–41 Moreover, high leptin levels associated with HFF diet indirectly induce the phosphorylation of ACACA.⁴² Furthermore, Mao et al.⁴³ showed that by the inhibition of ACACA enzyme, liver triglyceride level decreases. In addition, Savage et al.⁴⁴ stated that by inhibiting ACACA mRNA expression, amelioration of hepatic steatosis occurred.

PPAR-α shows prominent expression in hepatic cells with an important role in lipid metabolism, regulating fatty acid uptake, β-oxidation of fatty acids, and turnover of triglycerides.⁴⁵ In addition, it exerts an anti-inflammatory effect via regulation of NF-κB.⁴⁶ In this study, NASH induced upregulation in PPAR-α gene expression, which was insignificantly reduced by ADF intervention. Patsouris et al.⁴⁷ stated that administration of HFF diet to mice leads to induction of PPAR-α as a protective mechanism against HFF-induced steatosis as reported in several models.^48,49 On the contrary, other results showed that PPAR-α could not ameliorate steatosis,⁵⁰ and one research even reported that PPAR-α can induce steatosis.⁵¹ So, the role of pharmacological agonists of PPAR-α in managing steatosis is not consistent.

Bcl-2 is known to play a key regulatory role in the antiapoptotic process.⁵² In this study, it was amazing to find that Bcl-2 gene expression was upregulated in the NASH group and was downregulated by ADF. Bcl-2 upregulation in NASH might be explained as an adaptive response to resist apoptosis triggered by stressful lipid accumulation.⁵³ However, the apoptotic response was predominant, meaning that Bcl-2 upregulation was not enough to protect against apoptosis.⁵⁴

This study indicates that caspase-3-related apoptosis may have an important role in the progress of NASH,⁵⁵ showing significant increased expression in the NASH group. In addition, ADF was able to significantly attenuate that activation. Lipotoxicity-related stress may explain this, as it causes an increased production of reactive oxygen species (ROS) in the mitochondria of hepatocytes, and when this exceeds the capacity of scavengers, it leads to cellular damage.⁵⁶ As a response, caspase-3 is released from mitochondria to initiate the apoptotic pathway.⁵⁷

This study found that p53 may have an important metabolic role in the pathogenesis of NASH, showing significant increased expression in the NASH group. In addition, ADF was able to significantly attenuate it. These findings can be explained by the fact that p53 regulates production of ROS, cell senescence, and apoptosis.⁵⁸ P53 was also increasingly demonstrated as a key player in lipid metabolism. P53 exerts beneficial effects, being a regulator of β-oxidation of fatty acids as a trial for keeping fatty acids and triglycerides within healthy limits. A study by Goldstein and Rotter⁵⁹ on NASH found moderate induction of p53 gene that did not affect cell viability or apoptosis, but p53 was able to stimulate fatty acid oxidation, inhibit lipogenesis, and alleviate inflammation. This confirms the effect of moderate activation of p53 on protection against NASH.^60,61 If these borders are exceeded, p53 levels become abnormally elevated and may stimulate apoptosis and progression of NASH, as seen in our study.

COX-2 is the enzyme responsible for synthesis of prostaglandin E2 from arachidonic acid.⁶² COX-2 gene expression showed that a significant increase in NASH group may be as a protective mechanism against HFD-induced damage by attenuating steatosis and inflammation, by inhibiting apoptotic pathways with decreasing profibrogenic markers, and by restricting hepatic stellate cell activation and extracellular matrix deposition. However, in contrast to this constitutive expression of COX-2, the induction of inflammatory reactive COX-2 in advanced pathological conditions is closely associated with nitric oxide (NO) production by inducible NO synthase, which may also lead to hepatic damage.⁶³ In this study, ADF intervention was associated with significant normalization of COX-2 expression, indicating attenuation of hepatic inflammation. This demonstrates another potential mechanism of protection by ADF against hepatotoxicity induced by HFF diet.

Autophagy is the mechanism through which the organelles are isolated in membranes and then fuse with lysosomes for degradation and to be recycled for energy production. LC3 is a main constituent for the expansion of the autophagosomal isolation membrane, and p62 is responsible for selective autophagy of cytoplasmic ubiquitinated/aggregated proteins; hence, both are tangled in macroautophagy.⁶⁴ This study found that HFF diet inhibited autophagy indicated by decreased LC3 activity and increased P62 accumulation, demonstrating the inhibition of autophagic flux.⁶⁵ We found that ADF could restore the autophagic machinery with increased LC3 and decreased P62 expression, and this may be the main mechanism underlying the role of ADF in managing HFF diet-induced NASH through inducing lipophagy, too.

Furthermore, we found a significant correlation for the morphometric findings; Oil Red–stained and Sirius Red–stained area fractions as well as NAS with the levels of gene expression showed that all three morphometric parameters had a statistically significant positive correlation with ACACA, PPAR-α, caspase-3, p53, and COX-2 gene expression. This correlation can make the gene expression serve as a proxy for severity However, there was no statistically significant correlation between caspase-3 and morphometric parameters.

The results indicated that ADF, regardless of the decreased calorie intake, could ameliorate HFF diet–induced serum LDH elevation and hepatic histological alterations with less steatosis, inflammation, ballooning, fibrosis, and histopathological score as seen in H&E-stained sections, less steatosis in Oil Red O–stained sections, and decreased fibrosis as seen in Sirius Red–stained sections. Moreover, ADF ameliorated the HFF diet–induced alteration of hepatic lipogenic, inflammatory, proapoptotic, antiapoptotic, and autophagy markers ACACA, PPAR-γ, caspase-3, p53, COX-2, LC3, and P62, independent of weight loss. Coupled with an antilipogenic capacity and autophagy-enhancing, antiapoptotic, and anti-inflammatory effects of ADF, it may be clinically beneficial as a safe substitute to current therapeutic options. A graphical abstract describing the finding is presented in Fig. 8.

Figure 8.

Graphical abstract for the experiment, with representative photomicrographs of hematoxylin and eosin–stained liver sections (×400). Scale bar = 50µm. Abbreviations: HFF, high-fat-fructose; NASH, non-alcoholic steatohepatitis; ADF, alternate-day fasting, ACACA, acetyl CoA carboxylase; PPAR-γ, peroxisome proliferator-activated receptor-γ; PPAR-α, peroxisome proliferator-activated receptor-α; p53, tumor protein p53; Bcl-2, B-cell lymphoma 2; COX-2, cyclo-oxygenase 2; LC3, Microtubule-associated proteins light chain 3.

Footnotes

Acknowledgements

The authors express their gratitude to King Khalid University, Saudi Arabia, for providing administrative and technical support.

Competing Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Author Contributions

HRHE was involved in conceptualization, methodology, histopathology, morphometry, statistical analysis, and publishing, ME-N and RE-G were involved in conceptualization, methodology, molecular workup, statistical analysis, and validation. BAK was involved in conceptualization, methodology, and histopathology. RNS and MMA-E were involved in conceptualization, supervision, and revision. WFE was involved in histopathology consultation. AMA and EMEN were involved in supervision and revision. Each author has read and approved the manuscript before submission.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The authors extend their appreciation to the Deanship of Scientific Research at King Khalid University for funding this project through the research group program under grant number R.G.P. 1/217/41.

References

Younossi

Marchesini

Pinto-Cortez

Petta

. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: implications for liver transplantation. Transplantation. 2019;103(1):22–7.

Chalasani

Younossi

Lavine

Charlton

Cusi

Rinella

Harrison

Brunt

Sanyal

. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–57.

Patterson

Sears

. Metabolic effects of intermittent fasting. Annu Rev Nutr. 2017;37:371–93.

Longo

Mattson

. Fasting: molecular mechanisms and clinical applications. Cell Metab. 2014;19(2):181–92.

Yang

Cao

Mao

Wei

Chen

Zhang

Wang

Shi

Huang

Yao

Liu

. Alternate-day fasting protects the livers of mice against high-fat diet-induced inflammation associated with the suppression of toll-like receptor 4/nuclear factor kappaB signaling. Nutr Res. 2016;36(6):586–93. doi:10.1016/j.nutres.2016.02.001.

DiNicolantonio

McCarty

. Autophagy-induced degradation of Notch1, achieved through intermittent fasting, may promote beta cell neogenesis: implications for reversal of type 2 diabetes. Open Heart. 2019;6(1):e001028.

Chen

Montagner

Tan

Wahli

. Insights into the Role of PPARβ/δ in NAFLD. Int J Mol Sci. 2018;19(7):1893.

Kanda

Matsuoka

Yamazaki

Shibata

Nirei

Takahashi

Kaneko

Fujisawa

Higuchi

Nakamura

. Apoptosis and non-alcoholic fatty liver diseases. World J Gastroenterol. 2018;24(25):2661.

Ahmed

Saeed

Arshad

Afzaal

Imran

Ali

Niaz

Ahmad

Imran

. Impact of intermittent fasting on human health: an extended review of metabolic cascades. Int J Food Prop. 2018;21(1):2700–13.

10.

Faul

Erdfelder

Buchner

Lang

. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009;41(4):1149–60.

11.

Choi

Jin

Choi

Kim

Lee

Chung

Kim

Lee

Jeong

. Saponins from the roots of Platycodon grandiflorum ameliorate high fat diet-induced non-alcoholic steatohepatitis. Biomed Pharmacother. 2017;86:205–12. doi:10.1016/j.biopha.2016.11.107.

12.

Ying

. Therapeutic effect of gypenosides on nonalcoholic steatohepatitis via regulating hepatic lipogenesis and fatty acid oxidation. Biol Pharm Bull. 2017;40(5):650–7.

13.

Liu

Ming

Zhang

Chen

Zeng

Mao

. Gene-metabolite network analysis in different nonalcoholic fatty liver disease phenotypes. Exp Mol Med. 2017;49(1):e283.

14.

Yang

Wang

Shi

Dong

Zeng

Yang

. Mitochondrial dysfunction in high-fat diet-induced nonalcoholic fatty liver disease: the alleviating effect and its mechanism of Polygonatum kingianum. Biomed Pharmacother. 2019;117:109083. doi:10.1016/j.biopha.2019.109083.

15.

Christensen

Glavind

Thomsen

Kim

Heebøll

Schuppan

Hamilton-Dutoit

Würtz Heegaard

Grønbæk

. Niemann-Pick type C2 protein supplementation in experimental non-alcoholic fatty liver disease. PLOS ONE. 2018;13(3):e0192728. doi:10.1371/journal.pone.0192728.

16.

Sylvester Darvin

Toppo

Esakkimuthu

Ajeesh Krishna

Ceasar

Stalin

Balakrishna

Muniappan

Pazhanivel

Mahaprabhu

Paulraj

Pandikumar

Ignacimuthu

Al-Dhabi

. Hepatoprotective effect of bisbenzylisoquinoline alkaloid tiliamosine from Tiliacora racemosa in high-fat diet/diethylnitrosamine-induced non-alcoholic steatohepatitis. Biomed Pharmacother. 2018;108:963–73. doi:10.1016/j.biopha.2018.09.116.

17.

Kucera

Cervinkova

. Experimental models of non-alcoholic fatty liver disease in rats. World J Gastroenterol. 2014;20(26):8364.

18.

Jensen

Hvid

Damgaard

Nygaard

Ingvorsen

Wulff

Lykkesfeldt

Fledelius

. Dietary fat stimulates development of NAFLD more potently than dietary fructose in Sprague-Dawley rats. Diabetol Metab Syndr. 2018;10:4. doi:10.1186/s13098-018-0307-8.

19.

Burtis

Ashwood

. Tietz textbook of clinical chemistry. Philadelphia: W.B. Saunders; 1999. p. 1654–5.

20.

Elsayed

HRH

Anbar

Rabei

Adel

El-Gamal

. Eicosapentaenoic and docosahexaenoic acids attenuate methotrexate-induced apoptosis and suppression of splenic T, B-Lymphocytes and macrophages with modulation of expression of CD3, CD20 and CD68. Tissue and Cell. 2021;72:101533.

21.

Primer3 web. 2019 [cited 2019 July 5]. Available from: http://primer3.ut.ee

22.

Primer- BLAST. 2019 [cited 2019 July 5]. Available from: https://www.ncbi.nlm.nih.gov/tools/primer-blast/

23.

Livak

Schmittgen

. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta C(T)) Method. Methods. 2001;25(4):402–8.

24.

Layman

Pereira

Chellan

Huisamen

Kotzé

. A histomorphometric study on the hepatoprotective effects of a green rooibos extract in a diet-induced obese rat model. Acta Histochem. 2019;121(5):646–56.

25.

Bisen

. Laboratory protocols in applied life sciences. Hoboken: Taylor & Francis; 2014.

26.

Brunt

Janney

Di Bisceglie

Neuschwander-Tetri

Bacon

. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94(9):2467–74.

27.

Elsayed

HRH

El-Nablaway

Othman

Abdalla

El Nashar

Abd-Elmonem

El-Gamal

. Can dasatinib ameliorate the hepatic changes, induced by long term western diet, in mice? Ann Anat. 2020;234:151626. doi:10.1016/j.aanat.2020.151626.

28.

Schneider

Rasband

Eliceiri

. NIH image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9(7):671–5.

29.

Schindelin

Arganda-Carreras

Frise

Kaynig

Longair

Pietzsch

Preibisch

Rueden

Saalfeld

Schmid

. Fiji: an open-source platform for biological-image analysis. Nature Method. 2012;9(7):676–82.

30.

Renaud

Cui

Klaassen

. Effect of diet on expression of genes involved in lipid metabolism, oxidative stress, and inflammation in mouse liver–insights into mechanisms of hepatic steatosis. PLOS ONE. 2014;9(2):e88584.

31.

Fraulob

Ogg-Diamantino

Fernandes-Santos

Aguila

Mandarim-de-Lacerda

. A mouse model of metabolic syndrome: insulin resistance, fatty liver and non-alcoholic fatty pancreas disease (NAFPD) in C57BL/6 mice fed a high fat diet. J Clin Biochem Nutr. 2010;46(3):212–23.

32.

Harvie

Howell

. Potential benefits and harms of intermittent energy restriction and intermittent fasting amongst obese, overweight and normal weight subjects—a narrative review of human and animal evidence. Behav Sci. 2017;7(1):4.

33.

Elsayed

HRH

El Nashar

Abd-Elmonem

. Is the hepatocyte ultrastructural zonal heterogeneity changed by overnight (16 h) fasting? Morphometric study. Ultrastruct Pathol. 2019;43(6):290–300.

34.

Jensen

Kiersgaard

Sørensen

Mikkelsen

. Fasting of mice: a review. Lab Anim. 2013;47(4):225–40.

35.

Zhou

Jiang

Wang

Hua

Zhang

. Chicory (Cichorium intybus L.) Polysaccharides attenuate high-fat diet induced non-alcoholic fatty liver disease via AMPK activation. Int J Biol Macromol. 2018;118(PtA): 886–95.

36.

Skat-Rordam

Hojland Ipsen

Lykkesfeldt

Tveden-Nyborg

. A role of peroxisome proliferator-activated receptor gamma in non-alcoholic fatty liver disease. Basic Clin Pharmacol Toxicol. 2019;124(5):528–37.

37.

Matsusue

Haluzik

Lambert

Yim

S-H

Gavrilova

Ward

Brewer

Reitman

Gonzalez

. Liver-specific disruption of PPARγ in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J Clin Invest. 2003;111(5):737–47.

38.

Rotman

Sanyal

. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Gut. 2017;66(1):180–90.

39.

Wang

Botolin

Christian

Mitchell

Jayaprakasam

Nair

Peters

Busik

Olson

Jump

. Regulation of hepatic fatty acid elongase and desaturase expression in diabetes and obesity. J Lipid Res. 2006;47(9):2028–41. doi:10.1194/jlr.M600177-JLR200.

40.

Wang

Botolin

Christian

Busik

Jump

. Tissue-specific, nutritional, and developmental regulation of rat fatty acid elongases. J Lipid Res. 2005;46(4):706–15.

41.

Jump

. N-3 polyunsaturated fatty acid regulation of hepatic gene transcription. Curr Opin Lipidol. 2008;19(3):242–7.

42.

Unger

Scherer

. Gluttony, sloth and the metabolic syndrome: a roadmap to lipotoxicity. Trends Endocrinol Metab. 2010;21(6):345–52.

43.

Mao

DeMayo

Abu-Elheiga

Shaikenov

Kordari

Chirala

Heird

Wakil

. Liver-specific deletion of acetyl-CoA carboxylase 1 reduces hepatic triglyceride accumulation without affecting glucose homeostasis. Proc Natl Acad Sci USA. 2006;103(22):8552–7. doi:10.1073/pnas.0603115103.

44.

Savage

Choi

Samuel

Liu

Zhang

Wang

Zhang

Cline

Geisler

Bhanot

Monia

Shulman

. Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. J Clin Invest. 2006;116(3):817–24. doi:10.1172/JCI27300.

45.

Cave

Clair

Hardesty

Falkner

Feng

Clark

Sidey

Shi

Aqel

McClain

. Nuclear receptors and nonalcoholic fatty liver disease. Biochim Biophys Acta. 2016;1859(9):1083–99.

46.

Berghe

Vermeulen

Delerive

De Bosscher

Staels

Haegeman

. A paradigm for gene regulation: inflammation, NF-κB and PPAR. Adv Exp Med Biol. 2003;544:181–96.

47.

Patsouris

Reddy

Müller

Kersten

. Peroxisome proliferator-activated receptor α mediates the effects of high-fat diet on hepatic gene expression. Endocrinology. 2006;147(3):1508–16.

48.

Pawlak

Lefebvre

Staels

. Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J Hepatol. 2015;62(3):720–33.

49.

Ratziu

Harrison

Francque

Bedossa

Lehert

Serfaty

Romero-Gomez

Boursier

Abdelmalek

Caldwell

. Elafibranor, an agonist of the peroxisome proliferator− activated receptor− α and− δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology. 2016;150(5):1147–59.

50.

Fernández-Miranda

Pérez-Carreras

Colina

López-Alonso

Vargas

Solís-Herruzo

. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis. 2008;40(3):200–5.

51.

Yan

Wang

Cao

Zhou

Wang

Jing

Chen

Gao

. Peroxisome proliferator-activated receptor α activation induces hepatic steatosis, suggesting an adverse effect. PLOS ONE. 2014;9(6):e99245.

52.

Jin

Dai

C-L

. Attenuation of reperfusion-induced hepatocyte apoptosis is associated with reversed bcl-2/bax ratio in hemi-hepatic artery-preserved portal occlusion. J Surg Res. 2012;174(2):298–304.

53.

Mattson

Camandola

. NF-κB in neuronal plasticity and neurodegenerative disorders. J Clin Invest. 2001;107(3):247–54.

54.

Ramalho

Cortez-Pinto

Castro

Solá

Costa

Moura

Camilo

Rodrigues

. Apoptosis and Bcl-2 expression in the livers of patients with steatohepatitis. Eur J Gastroenterol Hepatol. 2006;18(1):21–9. doi:10.1097/00042737-200601000.

55.

Yadav

Sindram

Perry

Clavien

. Ischemic preconditioning protects the mouse liver by inhibition of apoptosis through a caspase-dependent pathway. Hepatology. 1999;30(5):1223–31.

56.

Circu

. Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic Biol Med. 2010;48(6):749–62.

57.

Perry

Smyth

Stennicke

Salvesen

Duriez

Poirier

Hannun

. Zinc is a potent inhibitor of the apoptotic protease, caspase-3 a novel target for zinc in the inhibition of apoptosis. J Biol Chem. 1997;272(30):18530–3.

58.

Yan

Miao

Zhang

Xie

. p53 as a double-edged sword in the progression of non-alcoholic fatty liver disease. Life Sci. 2018;215:64–72.

59.

Goldstein

Rotter

. Regulation of lipid metabolism by p53—fighting two villains with one sword. Trends Endocrinol Metab. 2012;23(11):567–75.

60.

Yahagi

Shimano

Matsuzaka

Najima

Sekiya

Nakagawa

Ide

Tomita

Okazaki

Tamura

Iizuka

Ohashi

Gotoda

Nagai

Kimura

Ishibashi

Osuga

Yamada

. p53 Activation in adipocytes of obese mice. J Biol Chem. 2003;278(28):25395–400. doi:10.1074/jbc.M302364200.

61.

Porteiro

Fondevila

Buque

Gonzalez-Rellan

Fernandez

Mora

Beiroa

Senra

Gallego

Fernø

López

Sabio

Dieguez

Aspichueta

Nogueiras

. Pharmacological stimulation of p53 with low-dose doxorubicin ameliorates diet-induced nonalcoholic steatosis and steatohepatitis. Mol Metab. 2018;8:132–43. doi:10.1016/j.molmet.2017.12.005.

62.

Chun

K-S

Surh

Y-J

. Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention. Biochem Pharmacol. 2004;68(6):1089–100.

63.

Chan

Liao

Hsieh

. The dualistic effect of COX-2-mediated signaling in obesity and insulin resistance. Int J Mol Sci. 2019;20(13):3115.

64.

Yamamoto

Kamata

Miura

Nagata

Kainuma

Ishii

. Differential adaptive responses to 1-or 2-day fasting in various mouse tissues revealed by quantitative PCR analysis. FEBS Open Bio. 2015;5:357–68.

65.

Carotti

Aquilano

Zalfa

Ruggiero

Valentini

Zingariello

Francesconi

Perrone

Alletto

Antonelli-Incalzi

. Lipophagy impairment is associated with disease progression in NAFLD. Front Physiol. 2020;11:850.